? Dana-Farber is lending a hand to little OncoSec?s nascent effort to develop CAR-T therapies for solid tumor cancers. The San Diego biotech has worked out an exclusive licensing deal with Wayne Marasco ? an expert in antibody engineering ? to apply his method of linking two single-chain variable fragment (scFv) in a bispecific CAR-T such that the T cells are only activated when both targets are engaged, thereby limiting off-tumor toxicity. OncoSec?s financial contribution in the research, which involves testing the experimental treatment solo and in combination with Tavo in triple-negative breast cancer, will be ?modest? and spread over several years, CEO Daniel O?Connor said.